Skip to content

Clarivate CLVT Life Sciences & Healthcare — Goodwill

Other segment segments

A&G
$1.09B
IP
$0

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Goodwill
$462M-0.9%
ExlService Holdings logo
EXLSHealthcare and Life Sciences — Goodwill
$189.57M0.0%
Donaldson Company logo
DCILife Sciences Segment — Goodwill
$172.8M+2.2%
Danaher logo
DHRLife Sciences — Goodwill
$12.78B-0.8%
Ashland logo
ASHLife Sciences — Goodwill Gross
$841M0.0%
Ecolab logo
ECLGlobal Healthcare And Life Sciences — Goodwill
$2.51B+5.0%

Other financials

Income statement

See full
Revenue$587.3M-5.5%
Gross profit$401.8M-3.8%
Operating income-$200.2M-3,001%
Net income-$268.6M-273%
EPS (diluted)-$0.42-282%

Balance sheet

See full
Cash & equivalents$217.7M-40.0%
Total debt$4.3B-7.4%
Total equity$4.5B-9.1%
Total assets$10.5B-8.2%

Cash flow

See full
Operating cash flow$98.7M-15.1%
CapEx$54.7M-17.1%
Free cash flow$44.0M-12.5%

Valuation

See full
Market cap$1.53B-46.9%
Enterprise value$5.64B-21.6%
P/S0.6×-0.5×

Profitability

See full
Gross margin66.8%+0.8pp
Operating margin-3.5%+5.5pp
Net margin-14%-2.3pp
FCF margin13.6%-0.3pp

Returns & leverage

See full
Return on equity-7.1%-0.8pp
Debt / equity0.0×
Current ratio0.8×-0.1×

Where this comes from

Reported directly by Clarivate in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Clarivate’s 10-Q, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Clarivate's life sciences & healthcare — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Clarivate's life sciences & healthcare — goodwill?
Clarivate (CLVT) reported life sciences & healthcare — goodwill of $256.1M in Q2 2026.
What does life sciences & healthcare — goodwill mean?
This represents the intangible asset value recorded when the segment acquires other businesses for a premium over their net identifiable assets. Changes in this balance, particularly through impairments, signal shifts in the long-term valuation and strategic viability of past acquisitions.